| Literature DB >> 29191131 |
Taryn Sleger1, Eric Gangl2, Petar Pop-Damkov2, Kevin M Krause3, Peter J Laud4, Andrew M Slee1, Wright W Nichols2.
Abstract
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess model in the rat. Efficacies corresponded to minimum inhibitory concentrations (MICs) measured in vitro and were consistent with drug exposures modelled from pharmacokinetics in infected animals. The ceftazidime, ceftazidime-avibactam and meropenem control treatments were effective in the rat abscess model against the susceptible strain, whereas only ceftazidime-avibactam was effective against K. pneumoniae harbouring blaKPC-2.Entities:
Keywords: Abscess infection; Ceftazidime–avibactam; KPC; Klebsiella pneumoniae; Rat pharmacokinetics
Mesh:
Substances:
Year: 2017 PMID: 29191131 DOI: 10.1080/1120009X.2017.1405609
Source DB: PubMed Journal: J Chemother ISSN: 1120-009X Impact factor: 1.714